Temsirolimus for treatment of kidney cancer renal cell carcinoma

Temsirolimus thats known as of CCI-779 can greatly improve the overall survival for patients and sufferers having the kidney cancer known as metastatic renal cell cancer. Temsirolimus could provide greater benefit to sufferers having less extensive metastatic disease.

Asthenia, anemia, nausea, dyspnea, and rash have been found to be the most common side effects associated with temsirolimus.

Temsirolimus blocks the function of the mammalian target of rapamycin (mTOR), a key protein inside cells that has been found to regulate cell proliferation, growth and survival. Temsirolimus may also block angiogenesis, a process that tumors use to create a blood supply to maintain their growth.

Renal cell carcinoma (RCC) is the most common type of kidney cancer that affect hundreds of thousands of kidney cancer patients from all over the world.